Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Front Biosci (Landmark Ed). 2021 11 30; 26(11):1286-1304.FB

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts have resulted in the development of at least 64 vaccine candidates that have reached Phase I to III clinical trials within 14 months. The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against COVID-19. Three COVID-19 vaccines (BNT162b2, mRNA-1273 and Sputnik V) in clinical Phase III trials have now achieved >90% efficacy in preventing COVID-19. Since SARS-CoV-2 is highly contagious, vaccines are expected to achieve at least 80% herd immunity in the world's population to effectively prevent SARS-CoV-2 infections. An overview of safety, immunogenicity and efficacy of the current frontrunner vaccines are reviewed.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Lim HX
Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, Malaysia.
Arip M
Allergy and Immunology Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia.
Yahaya AAA
Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, Malaysia.
Jazayeri SD
Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, Malaysia. Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Poppema S
School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, Malaysia.
Poh CL
Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor, Malaysia.

MeSH

Antibodies, ViralCOVID-19COVID-19 VaccinesClinical Trials as TopicHumansPandemicsSARS-CoV-2

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34856768

Citation

Lim, Hui Xuan, et al. "Immunogenicity and Safety of SARS-CoV-2 Vaccines in Clinical Trials." Frontiers in Bioscience (Landmark Edition), vol. 26, no. 11, 2021, pp. 1286-1304.
Lim HX, Arip M, Yahaya AAA, et al. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Front Biosci (Landmark Ed). 2021;26(11):1286-1304.
Lim, H. X., Arip, M., Yahaya, A. A. A., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2021). Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Frontiers in Bioscience (Landmark Edition), 26(11), 1286-1304. https://doi.org/10.52586/5024
Lim HX, et al. Immunogenicity and Safety of SARS-CoV-2 Vaccines in Clinical Trials. Front Biosci (Landmark Ed). 2021 11 30;26(11):1286-1304. PubMed PMID: 34856768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. AU - Lim,Hui Xuan, AU - Arip,Masita, AU - Yahaya,Abdul Aziz Al-Fattah, AU - Jazayeri,Seyed Davoud, AU - Poppema,Sibrandes, AU - Poh,Chit Laa, PY - 2021/06/11/received PY - 2021/09/24/revised PY - 2021/09/24/accepted PY - 2021/12/3/entrez PY - 2021/12/4/pubmed PY - 2021/12/15/medline KW - Immunogenicity KW - SARS-CoV-2 KW - Safety KW - Vaccines SP - 1286 EP - 1304 JF - Frontiers in bioscience (Landmark edition) JO - Front Biosci (Landmark Ed) VL - 26 IS - 11 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were first detected in Wuhan, China in December 2019 and resulted in a worldwide pandemic in 2020. SARS-CoV-2 infections totalled more than 180 million with 3.9 million deaths as of June 24, 2021. Tremendous research efforts have resulted in the development of at least 64 vaccine candidates that have reached Phase I to III clinical trials within 14 months. The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against COVID-19. Three COVID-19 vaccines (BNT162b2, mRNA-1273 and Sputnik V) in clinical Phase III trials have now achieved >90% efficacy in preventing COVID-19. Since SARS-CoV-2 is highly contagious, vaccines are expected to achieve at least 80% herd immunity in the world's population to effectively prevent SARS-CoV-2 infections. An overview of safety, immunogenicity and efficacy of the current frontrunner vaccines are reviewed. SN - 2768-6698 UR - https://www.unboundmedicine.com/medline/citation/34856768/Immunogenicity_and_safety_of_SARS_CoV_2_vaccines_in_clinical_trials_ DB - PRIME DP - Unbound Medicine ER -